| Entry |
|
|---|
| Name |
Trastuzumab and hyaluronidase;
Trastuzumab and hyaluronidase-oysk;
Herceptin hylecta (TN) |
|---|
| Product |
|
|---|
| Component |
Trastuzumab [DR: D03257], Hyaluronidase (human recombinant) [DR: D06604]
|
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03158 HER2 inhibitor
|
|---|
| Remark |
|
|---|
| Efficacy |
Antineoplastic (adjuvant) |
|---|
| Disease |
Breast cancer (HER2 overexpressing or ER/PR negative) [DS: H00031] |
|---|
| Type |
Monoclonal antibody, combination |
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
L01FD01 Trastuzumab
D11560 Trastuzumab and hyaluronidase <US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Hyaluronidase/ Trastuzumab
D11560 Trastuzumab and hyaluronidase
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03158 HER2 inhibitor
D11560 Trastuzumab and hyaluronidase
Drug classes [BR:br08332]
Antineoplastic
DG03158 HER2 inhibitor
D11560 Trastuzumab and hyaluronidase
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
